Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 4:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sequence 1 Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments

NCT03288207
View directory record Official record
Conditions
Obesity
Interventions
AMRA(r) Researcher Image reconstruction software, MRI: radiofrequency coils (Device Manufacturer: Siemens Medical Solutions USA, Inc.), MRI: Research pulse sequences (Device Manufacturer: NIH), MRI: Image Reconstruction and Analysis Software (Device Manufacturer: NIH), Bluetooth-enabled glucometer, Remote tailored-to-place coaching (TPC), Standard remote coaching (SRC), Run-in physical-activity monitoring, Ambulatory blood-pressure monitor, Polysomnography equipment
Device · Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 75 Years · Female only
Enrollment
325 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 15, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

NCT02018536
View directory record Official record
Conditions
Healthy
Interventions
GSK2336805 30 mg, GSK2336805 60 mg, GSK2336805 120 mg, TMC435 150 mg (Treatment A), GSK2336805 60 mg (Treatment B and part of Treatment C and D), TMC435 100 mg (part of Treatment C), TMC435 150 mg (part of treatment D)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 15, 2026, 4:08 PM EDT
Completed Not applicable Interventional Results available

Effects of rTMS on Brain Activation in Aphasia

NCT03292471
View directory record Official record
Conditions
Aphasia, Acquired
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 15, 2026, 4:08 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

MiBo ThermoFlo Lid Temperature Evaluation

NCT03787212
View directory record Official record
Conditions
Dry Eye
Interventions
MiBo ThermoFlo, Bruder Mask
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 15, 2026, 4:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Personalized Trials for Stress Management Against Standard of Care

NCT05408832
View directory record Official record
Conditions
Stress
Interventions
Personalized Trial ABCCBA, Personalized Trial CBAABC, Stress Management Techniques with No Randomization Sequence (or order)
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 15, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants

NCT04608344
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Atorvastatin, Pravastatin, Rosuvastatin, Filgotinib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 15, 2026, 4:08 PM EDT
Completed Phase 1 Interventional

A In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract

NCT01630798
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
GI heptapeptide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Sep 15, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants

NCT05277012
View directory record Official record
Conditions
Healthy Participants
Interventions
Etrumadenant
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 15, 2026, 4:08 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Heart Transplantation - Renewal

NCT05521399
View directory record Official record
Conditions
Transplant, Heart, Magnetic Resonance Imaging
Interventions
MRI Sequencing, MRI Testing (pediatric), MRI Testing
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
247 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 15, 2026, 4:08 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

NCT06270316
View directory record Official record
Conditions
Fabry Disease
Interventions
AMT-191
Drug
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 15, 2026, 4:08 PM EDT
Completed Phase 2 Interventional Results available

AD109 Dose Finding in Mild to Moderate OSA

NCT04631107
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
AD109 dose1- A, AD109 dose2- B, Placebo- C
Drug
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
San Diego, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 15, 2026, 4:08 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

NCT00927758
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 15, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

NCT03649165
View directory record Official record
Conditions
Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Acetaminophen
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Sep 15, 2026, 4:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of a Daily Disposable Novel Multifocal Contact Lens in a Myopic Population; Part 2

NCT04615507
View directory record Official record
Conditions
Visual Acuity
Interventions
JJVC Investigational Multifocal Contact Lens, Dailies Total 1® Multifocal Contact Lens
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
6
States / cities
Jacksonville, Florida • Roswell, Georgia • Raytown, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Sep 15, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib

NCT02131298
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib Alone, Palbociclib plus itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 29, 2014 · Synced Sep 15, 2026, 4:08 PM EDT
Active, not recruiting No phase listed Observational

A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis

NCT03127709
View directory record Official record
Conditions
Histiocytosis
Interventions
Trail Making Test, Parts A & B, Brief Test of Attention, Symbol Span, Controlled Oral Word Association Test, The Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Hospital Anxiety and Depression Scale, McGill Quality of Life Scale, MR Brain Imaging, Resting state functional MRI, Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)
Behavioral · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 15, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between Dolutegravir and Prednisone

NCT01425099
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir, Prednisone
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Sep 15, 2026, 4:08 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants

NCT05205447
View directory record Official record
Conditions
Healthy
Interventions
LY3410738, Itraconazole, Carbamazepine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Sep 15, 2026, 4:08 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Prospective Study of Induction Medications Used in the Trauma RSI

NCT04291521
View directory record Official record
Conditions
Trauma, Rapid Sequence Intubation
Interventions
Ketamine, Etomidate, Propofol
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 15, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

NCT07007806
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting, Treatment B-Omeprazole 20 mg dose administered fasting, Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting, Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole, Treatment E-Omeprazole 40 mg administered fasting, Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 15, 2026, 4:08 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

NCT07723833
View directory record Official record
Conditions
Healthy Participants
Interventions
Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test formulation 1 Dose B, Elecoglipron Test formulation 2 Dose A, Elecoglipron Test formulation 2 Dose B
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 15, 2026, 4:08 PM EDT
Completed Phase 1Phase 2 Interventional

Ixabepilone Administered as an Enteric Coated Formulation.

NCT00309049
View directory record Official record
Conditions
Cancer
Interventions
Ixabepilone
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 15, 2026, 4:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Investigational Daily Disposable Multifocal Contact Lenses Produced With Different Manufacturing Processes in Myopes

NCT04889625
View directory record Official record
Conditions
Visual Acuity
Interventions
senofilcon A C3, Dailies Total 1® Multifocal Contact Lenses
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
6
States / cities
Jacksonville, Florida • Saint Augustine, Florida • Vestal, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Sep 15, 2026, 4:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects

NCT02082808
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG, DCV
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 15, 2026, 4:08 PM EDT